کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2407438 | 1103126 | 2007 | 9 صفحه PDF | دانلود رایگان |

A phase 1, dose-escalating trial was conducted in healthy adults to evaluate immunogenicity and reactogenicity of a type V group B streptococcal (GBS) capsular polysaccharide (CPS)–tetanus toxoid (TT) conjugate vaccine. Participants received one dose of unconjugated V CPS (37 μg), V–TT (2.4 μg CPS/1.1 μg TT), V–TT (9.6 μg CPS/4.3 μg TT) or V–TT (38.5 μg CPS/17.0 μg TT). Each vaccine and all doses of V–TT were well-tolerated. V CPS-specific antibodies reached a peak 4–8 weeks after immunization and were significantly higher through 52 weeks post-immunization in recipients of V–TT at each dose than in uncoupled CPS vaccinees. V–TT vaccine-induced antibodies promoted opsonophagocytic killing of type V GBS and avidity maturation of V CPS-specific IgG.
Journal: Vaccine - Volume 25, Issue 1, 2 January 2007, Pages 55–63